Cargando…

Booster of mRNA-1273 Strengthens SARS-CoV-2 Omicron Neutralization

The Omicron variant of SARS-CoV-2 is raising concerns because of its increased transmissibility and potential for reduced susceptibility to antibody neutralization. To assess the potential risk of this variant to existing vaccines, serum samples from mRNA-1273 vaccine recipients were tested for neut...

Descripción completa

Detalles Bibliográficos
Autores principales:	Doria-Rose, Nicole A., Shen, Xiaoying, Schmidt, Stephen D, O’Dell, Sijy, McDanal, Charlene, Feng, Wenhong, Tong, Jin, Eaton, Amanda, Maglinao, Maha, Tang, Haili, Manning, Kelly E., Edara, Venkata-Viswanadh, Lai, Lilin, Ellis, Madison, Moore, Kathryn, Floyd, Katharine, Foster, Stephanie L., Atmar, Robert L., Lyke, Kirsten E., Zhou, Tongqing, Wang, Lingshu, Zhang, Yi, Gaudinski, Martin R, Black, Walker P, Gordon, Ingelise, Guech, Mercy, Ledgerwood, Julie E, Misasi, John N, Widge, Alicia, Roberts, Paul C., Beigel, John, Korber, Bette, Pajon, Rolando, Mascola, John R., Suthar, Mehul S., Montefiori, David C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cold Spring Harbor Laboratory 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8687471/ https://www.ncbi.nlm.nih.gov/pubmed/34931200 http://dx.doi.org/10.1101/2021.12.15.21267805

Ejemplares similares

SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination
por: Pajon, Rolando, et al.
Publicado: (2022)

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
por: Doria-Rose, Nicole, et al.
Publicado: (2021)

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination
por: Widge, Alicia T., et al.
Publicado: (2020)

Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants
por: Pegu, Amarendra, et al.
Publicado: (2021)

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines
por: Shen, Xiaoying, et al.
Publicado: (2021)

Safety and Immunogenicity of a Third Dose of SARS-CoV-2 mRNA Vaccine – An Interim Analysis
por: Anderson, Evan, et al.
Publicado: (2022)

SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral Spike vaccines
por: Shen, Xiaoying, et al.
Publicado: (2021)

mRNA-1273 Vaccine-elicited Neutralization of SARS-CoV-2 Omicron in Adolescents and Children
por: Girard, Bethany, et al.
Publicado: (2022)

Original antigenic sin responses to Betacoronavirus spike proteins are observed in a mouse model, but are not apparent in children following SARS-CoV-2 infection
por: Lapp, Stacey A., et al.
Publicado: (2021)

Antibodies with potent and broad neutralizing activity against antigenically diverse and highly transmissible SARS-CoV-2 variants
por: Wang, Lingshu, et al.
Publicado: (2021)

Calibration of Two Validated SARS-CoV-2 Pseudovirus Neutralization Assays for COVID-19 Vaccine Evaluation
por: Huang, Yunda, et al.
Publicado: (2021)

Calibration of Two Validated SARS-CoV-2 Pseudovirus Neutralization Assays for COVID-19 Vaccine Evaluation
por: Huang, Yunda, et al.
Publicado: (2021)

Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation
por: Huang, Yunda, et al.
Publicado: (2021)

Phase I Randomized Clinical Trial of VRC DNA and rAd5 HIV-1 Vaccine Delivery by Intramuscular (IM), Subcutaneous (SC) and Intradermal (ID) Administration (VRC 011)
por: Enama, Mary E., et al.
Publicado: (2014)

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
por: Anderson, Evan J., et al.
Publicado: (2020)

DNA Vaccine Delivered by a Needle-Free Injection Device Improves Potency of Priming for Antibody and CD8+ T-Cell Responses after rAd5 Boost in a Randomized Clinical Trial
por: Graham, Barney S., et al.
Publicado: (2013)

Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clones
por: Lima, Noemia S., et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351
por: Shen, Xiaoying, et al.
Publicado: (2021)

Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants
por: Wang, Lingshu, et al.
Publicado: (2021)

Quantifying the Vaccine-Induced Humoral Immune Response to Spike-Receptor Binding Domain as a Surrogate for Neutralization Testing Following mRNA-1273 (Spikevax) Vaccination Against COVID-19
por: Kirste, Imke, et al.
Publicado: (2022)

Structural basis for potent neutralization of SARS-CoV-2 and role of antibody affinity maturation
por: Hurlburt, Nicholas K., et al.
Publicado: (2020)

Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clones
por: Lima, Noemia S., et al.
Publicado: (2022)

β-Catenin Regulates Wound Healing and IL-6 Expression in Activated Human Astrocytes
por: Edara, Venkata Viswanadh, et al.
Publicado: (2020)

Activated human astrocyte-derived extracellular vesicles modulate neuronal uptake, differentiation and firing
por: You, Yang, et al.
Publicado: (2019)

Primate immune responses to HIV-1 Env formulated in the saponin-based adjuvant AbISCO-100 in the presence or absence of TLR9 co-stimulation
por: Martinez, Paola, et al.
Publicado: (2015)

Randomized evaluation of an online single-session intervention for minority stress in LGBTQ+ adolescents
por: Shen, J., et al.
Publicado: (2023)

Antibody-Based HIV-1 Vaccines: Recent Developments and Future Directions: A summary report from a Global HIV Vaccine Enterprise Working Group
por: Montefiori, David, et al.
Publicado: (2007)

Durability of mRNA-1273 vaccine–induced antibodies against SARS-CoV-2 variants
por: Pegu, Amarendra, et al.
Publicado: (2021)

Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials
por: Gaudinski, Martin R, et al.
Publicado: (2018)

Functional Profiling of Antibody Immune Repertoires in Convalescent Zika Virus Disease Patients
por: Fahad, Ahmed S., et al.
Publicado: (2021)

Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults
por: Gaudinski, Martin R., et al.
Publicado: (2018)

Pre-existing SARS-CoV-2 immunity influences potency, breadth, and durability of the humoral response to SARS-CoV-2 vaccination
por: Mantus, Grace, et al.
Publicado: (2022)

Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529
por: Zhou, Tongqing, et al.
Publicado: (2022)

Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects
por: Jennewein, Madeleine F., et al.
Publicado: (2021)

Phase 1 Study of Pandemic H1 DNA Vaccine in Healthy Adults
por: Crank, Michelle C., et al.
Publicado: (2015)

DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials
por: Ledgerwood, Julie E, et al.
Publicado: (2011)

Convergent Evolution in Breadth of Two V(H)6-1-Encoded Influenza Antibody Clonotypes from a Single Donor
por: Wu, Nicholas C., et al.
Publicado: (2020)

Safety and immunogenicity of an HIV-1 prefusion-stabilized envelope trimer (Trimer 4571) vaccine in healthy adults: A first-in-human open-label, randomized, dose-escalation, phase 1 clinical trial
por: Houser, Katherine V., et al.
Publicado: (2022)

Panels of HIV-1 Subtype C Env Reference Strains for Standardized Neutralization Assessments
por: Hraber, Peter, et al.
Publicado: (2017)

Molecular basis of SARS-CoV-2 Omicron variant evasion from shared neutralizing antibody response
por: Patel, Anamika, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_32ae1ue4409j28k50n4j5ju1ed